South Africa proposes limiting drug patent extensions

04/23/2013 | PharmaLive.com

South Africa has announced plans to limit the ability of drug firms to win patent extensions for brand-name drugs by changing or modifying them in minor ways. Critics allege that such extensions block patients from receiving cheaper and more affordable versions of life-saving medications for such conditions as HIV/AIDS. The South African move comes barely a month after India rejected a patent extension request from Novartis for its best-selling Gleevec cancer treatment.

View Full Article in:

PharmaLive.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD